Research and Development, Sol-Gel Technologies Ltd., 7 Golda Meir Street, Ness Ziona, Israel.
Dermatol Ther. 2011 Sep-Oct;24(5):477-88. doi: 10.1111/j.1529-8019.2012.01464.x.
The introduction of new topical drugs based on new chemical entities has become a rare event. Instead, pharmaceutical companies have been focused on reformulating existing drugs resulting in an ever-growing number of topical drug products for every approved drug substance. In light of this trend, soon reformulations may not be as rewarding to their sponsors as they are today unless they offer a substantial improvement over other formulations of the same drug substance and the same indication, namely improved efficacy over existing drugs, reduced side effects, unique drug combinations, or applicability for new indications. This article reviews and compares topical drug delivery systems currently under active research that are designed to offer such advantages in the coming years. The reviewed delivery systems are: liposomes, niosomes, transferosomes, ethosomes, solid lipid nanoparticles, nanostructured lipid carriers, cyclodextrin, and sol-gel microcapsules. Among all the topical drug delivery systems currently undergoing active research, only the sol-gel microencapsulation is at clinical stages.
新型局部用药物的研发基于新的化学实体，这已成为罕见事件。相反，制药公司一直专注于对现有药物进行重新配方，导致每种已批准的药物物质都有越来越多的局部用药物产品。鉴于这一趋势，如果新配方不能提供比其他同类药物配方和相同适应症更好的实质性改进，即优于现有药物的疗效、减少副作用、独特的药物组合或适用于新适应症，那么它们对其赞助商的回报可能不如今天。本文综述和比较了目前正在积极研究的局部药物传递系统，旨在未来几年提供此类优势。综述的传递系统有：脂质体、非离子型脂质体、转胞体、醇质体、固体脂质纳米粒、纳米结构脂质载体、环糊精和溶胶-凝胶微胶囊。在目前正在积极研究的所有局部药物传递系统中，只有溶胶-凝胶微胶囊处于临床阶段。
